Arax Advisory Partners’s Treace Medical Concepts TMCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$66.4K Sell
14,949
-8,483
-36% -$38K ﹤0.01% 3114
2026
Q2
$93.3K Buy
+23,432
New +$64.4K ﹤0.01% 2788
2026
Q1
– Sell
-17
Closed -$42 – 4318
2025
Q4
$42 Sell
17
-3,547
-100% -$15.4K ﹤0.01% 3949
2025
Q3
$23.9K Buy
+3,564
New +$23.3K ﹤0.01% 2183
2025
Q2
– Sell
-106
Closed -$890 – 3191
2025
Q1
$890 Hold
106
– – ﹤0.01% 2339
2024
Q4
$789 Buy
+106
New +$709 ﹤0.01% 2221

Other funds holding TMCI

Arax Advisory Partners's TMCI Position: Q3 2026 in Review

Arax Advisory Partners reduced its Treace Medical Concepts (TMCI) stake by 36% in Q3 2026, selling an estimated $38K and leaving 14,949 shares worth $66.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3114.

Arax Advisory Partners first reported a position in TMCI in Q4 2024 and has held it in 6 quarters since. The position peaked at $93.3K in Q2 2026. 115 funds tracked by Wall St. Rank hold TMCI as of Q3 2026.

  • Arax Advisory Partners held 14,949 shares of Treace Medical Concepts worth $66.4K as of Q3 2026.
  • Arax Advisory Partners sold 8,483 Treace Medical Concepts shares in Q3 2026, an estimated $38K.
  • Treace Medical Concepts made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3114 holding.
  • Arax Advisory Partners first reported a position in Treace Medical Concepts in Q4 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Treace Medical Concepts position peaked at $93.3K in Q2 2026.
  • 115 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.